Total amount raised
$322.6 Millions
Latest funding date
07/01/2024
Location
Huma has successfully raised funds from a total of 16 investors, including HAT Sicaf and Leaps by Bayer. The company recently closed a Series D funding round on July 16, 2024.
Keep reading to explore the intricacies of Huma's fundraising journey and the investors backing this innovative platform.
What Is Huma?
Huma, founded on August 2, 2011, by Dan Vahdat and Rich Khatib, is a global health technology company based in London, England. The company specializes in providing a modular platform for digital 'hospitals at home,' integrating predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research.
Huma's platform supports remote patient monitoring, virtual wards, decentralized clinical trials, and companion apps for pharma and medtech. The company aims to help people live longer, fuller lives by offering digital-first care and research solutions.
With a workforce of 101-250 employees, Huma collaborates with governments, hospital groups, universities, and life science companies to enhance healthcare delivery and patient outcomes.
How Much Funding Has Huma Raised?
- Seed Round
- Amount Raised: $1M
- Date: January 2016
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's operations and initial development of its digital health platform.
- Series A
- Amount Raised: $28M
- Date: February 2018
- Lead Investors: NWS Holdings
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the platform's capabilities and scale operations.
- Series B
- Amount Raised: $50M
- Date: November 2019
- Lead Investors: Leaps by Bayer
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance the platform's features and increase market reach.
- Series C
- Amount Raised: $100M
- Date: May 2021
- Lead Investors: Hitachi Ventures, Leaps by Bayer
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the development of new digital health solutions and expand globally.
- Debt Financing
- Amount Raised: $30M
- Date: May 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To provide additional working capital for ongoing projects.
- Non-Equity Assistance
- Amount Raised: Not publicly disclosed
- Date: September 2021
- Lead Investors: Future Fifty
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To receive strategic support and resources for scaling the business.
- Corporate Round
- Amount Raised: £25M
- Date: March 2022
- Lead Investors: AstraZeneca
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To strengthen partnerships and enhance the platform's capabilities.
- Grant
- Amount Raised: £493.9K
- Date: January 2023
- Lead Investors: SBRI Healthcare
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund specific research and development projects.
- Series D
- Amount Raised: $80M
- Date: July 2024
- Lead Investors: AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, Leaps by Bayer
- Valuation at Round: Nearly $1 billion
- Motivation Behind the Round: To develop the Huma Cloud Platform and expand global reach.
Total Amount Raised: Over $300 million. Current Valuation: Nearly $1 billion.
Key Investors
- AstraZeneca
- Details: AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
- Investment Focus Areas: Biopharmaceuticals, oncology, cardiovascular, renal, and respiratory diseases.
- Notable Investments: Moderna, Viela Bio, Acerta Pharma.
- Leaps by Bayer
- Details: Leaps by Bayer is the impact investment arm of Bayer, focusing on breakthrough technologies in health and agriculture. The initiative aims to tackle some of the world's biggest challenges through transformative investments.
- Investment Focus Areas: Health, agriculture, biotechnology.
- Notable Investments: BlueRock Therapeutics, Joyn Bio, Century Therapeutics.
- Hitachi Ventures
- Details: Hitachi Ventures is the corporate venture capital arm of Hitachi, investing in innovative startups that align with Hitachi's business areas. The fund aims to foster innovation and create new business opportunities.
- Investment Focus Areas: Healthcare, IT, infrastructure, digital solutions.
- Notable Investments: Innoviz Technologies, Vayyar Imaging, PrecisionHawk.
- Hat Technology Fund 4 by HAT SGR
- Details: Hat Technology Fund 4 is a technology-focused investment fund managed by HAT SGR, an Italian asset management company. The fund invests in technology-driven companies with high growth potential.
- Investment Focus Areas: Technology, innovation, digital transformation.
- Notable Investments: Not publicly disclosed.
- NWS Holdings
- Details: NWS Holdings is an investment holding company with a diverse portfolio, including healthcare investments. The company is based in Hong Kong and operates in various sectors such as infrastructure, services, and transport.
- Investment Focus Areas: Healthcare, infrastructure, services, transport.
- Notable Investments: Not publicly disclosed.
What's Next for Huma?
Huma's future is brimming with opportunities, particularly with the expansion of its Huma Cloud Platform. This AI-powered ecosystem is set to revolutionize digital health by enabling rapid development and deployment of healthcare applications. With partnerships with tech giants like Google and a presence in over 3,000 hospitals and clinics, the platform's potential is vast, engaging millions of users globally.
As Huma continues to grow, future fundraising opportunities are likely. The success of the Series D round and the platform's scalability make it an attractive prospect for investors. Strategic acquisitions in the US and Europe could further enhance its capabilities and market reach.
However, challenges remain. Navigating regulatory compliance across multiple regions and ensuring data security are critical. Additionally, the competitive landscape of digital health and AI requires constant innovation. Despite these hurdles, Huma's strategic vision and robust platform position it well for continued success.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Huma and gather other critical business insights.
Sign up for free and start exploring the wealth of information available at Clay.
